According to the studies by Russcher [2], carriers of the ER22/23EK and 3669A > G variant presented a reduced transcriptional activity of the GR, which might translate into a reduced risk of T2DM and cardiovascular disorders as a result of a relative insensitivity to endogenous glucocorticosteroids [1]. This evidence concerns the gene NR3C1 and type 2 diabetes mellitus.